In Brief: Fujisawa
Fujisawa: Files appeal of the July 25 Chicago federal court summary judgment dismissal of its law suit against former Lyphomed Chairman and CEO John Kapoor. Fujisawa had filed the suit in 1992 alleging that Kapoor defrauded the company by filing false ANDA data with FDA between 1980-86 before the Japanese-based firm had acquired Lyphomed. Judge Elaine Bucklo "did not rule on the merits of the case but dismissed our claims on technical legal grounds," Fujisawa maintains. Kapoor maintains that Fujisawa "mismanaged" Lyphomed...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth